What factors drove the 9.13% increase in institutional ownership of CRMD shares in the most recent quarter?

The 9.13% increase in institutional ownership of CorMedix (CRMD) shares in the most recent quarter appears to be driven by a confluence of significant commercial milestones and strategic corporate developments. These factors collectively signal a positive shift in the company's growth trajectory and financial health, likely attracting increased institutional interest.

Key drivers include:

• Commercial Success of DefenCath: CorMedix's lead product, DefenCath, which received FDA approval in November 2023, has demonstrated robust commercial performance. The company launched DefenCath in inpatient settings in April 2024 and outpatient settings in July 2024.1 This led to a substantial increase in revenue, with Q2 2025 net revenue reaching $39.7 million, a significant jump from $0.8 million in the prior year period.2 Preliminary Q3 2025 unaudited net revenue exceeded $100 million, with DefenCath sales contributing over $85 million.3 This strong uptake and revenue growth likely instilled confidence in institutional investors.
• Strategic Acquisition of Melinta Therapeutics: CorMedix announced the acquisition of Melinta Therapeutics on August 7, 2025, completing the "transformational" deal by September 2, 2025.1 This acquisition significantly expands CorMedix's commercial product portfolio and is expected to be accretive to earnings per share, diversifying revenue streams and enhancing market presence.4
• Improved Financial Performance and Outlook: The company achieved its first profitable commercial quarter in Q4 2024, followed by strong profitability in Q1 2025, reporting $20.6 million in net income and $23.6 million in adjusted EBITDA.5 Q3 2025 continued this trend with $108.6 million in net income and $71.9 million in adjusted EBITDA.6 CorMedix also raised its full-year 2025 pro forma net revenue guidance, reflecting optimism about future performance.3
• Major Customer Implementations: In June 2025, CorMedix announced that a Large Dialysis Organization (LDO) customer began implementing DefenCath, targeting a significantly expanded patient base. This strategic customer win is expected to drive substantial revenue growth in the latter half of 2025.7

These developments collectively suggest that institutions are recognizing CorMedix's successful transition to a commercial-stage biopharmaceutical company with a growing product portfolio and improving financial metrics.